Skip to content
Company Analysis

Nyxoah SA NYXH

A comprehensive view of key metrics, scores, and financial health for Nyxoah SA

Overview of Nyxoah S.A.

NYXH NGM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Nyxoah S.A. (NYXH), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $0.88, about 0.0% overvalued vs fair value, -82.5% 1Y return, ranked 921/1145 in sector.
Metrics Rev Growth 121.6% ROE -110.9% Gross Margin 63.1% Div Yield 0.00%
USD 0.88
0.92%
(Delayed)
• Vol 90d: 74.7%
52-Week Range
Market Cap
$89.67M
Enterprise Value
$74.57M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Weak
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 100%
Confidence: 95%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.nyxoah.com
HQ Mont-Saint-Guibert
Employees 183
Fiscal year Dec 31

Next Events

Earnings Nov 5 Call: Nov 5

Fair Value Snapshot

Bear Base Bull
$-1
$-1
$-1
Current: $0.88

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
EUR 10.0M
121.6%%
Gross Profit
EUR 6.3M
113.1%%
Operating Income (GAAP)
-EUR 83.5M
-42%%
EBITDA
-EUR 82.7M
-56.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
63.1%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Nyxoah SA's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
45
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.81). This signals strong consumable attach-rate economics.
  • Stable Gross Margin Profile Gross margin stability is strong (score 0.85). Low volatility confirms durable consumable pricing.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.19). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Thin Interest Coverage Interest coverage lags peers (score 0.20). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
83
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing NYXH's balance between Growth (55.4%), Profitability (24.5%), and Safety (20.1%). Growth 55% Safety 20% Profitability 24%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

62th percentile vs peers
62
Key Signals
Rev Growth YoY 1.22 96p Revenue CAGR 3Y 48.1% 89p EPS Growth YoY -30.7% 19p TSR -42.5% 15p Asset Growth YoY -25.2% 11p
Strengths
  • Rev Growth YoY in top 20% of peers (1.22, 96th percentile)
  • Revenue CAGR 3Y in top 20% of peers (48.1%, 89th percentile)
  • Growth above peer median with strong metric coverage (85%)
Risks
  • EPS Growth YoY in bottom 20% of peers (-30.7%)

Profitability

27th percentile vs peers
28
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

22th percentile vs peers
23
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Nyxoah SA.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.28
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000